Biotechs have been battered but Celltech may be a long-term cure

Christmas will make or break Body Shop; Fibernet remains a perilous investment

Who would be a biotechnology analyst in the current market? The City's finest were in Slough yesterday listening to news on Celltech's portfolio of potential wonderdrugs, some of which might turn into blockbuster products in five, six, seven years' time. They were impressed, but all the while they knew that shaken, risk-averse equity investors are only interested in where this year's earnings and dividends are going to come from. Since they are not going to come from the biotech sector, shares continue to go down and down, however enthusiastic the analysts. There was a mood of some gloom.

Celltech forfeited its place in the FTSE 100, partly because of the widespread flight from jam-tomorrow biotech companies but mainly because of its own string of disappointments. At the start of the year, Celltech looked as if earnings were just round the corner. Now they are plainly not.

The company is on the verge of dropping its most advanced drug, Humicade, which had been close to launch as a treatment for Crohn's disease, which causes inflammation of the gut. Celltech has a more unequivocally effective treatment for the disease less than two years behind Humicade in the clinic, so there seems little point pursuing both. Great trial data on CDP 870, the second Crohn's treatment (which is also being developed as a treatment for rheumatoid arthritis by the mighty Pfizer and is Celltech's most exciting product) was the centrepiece of yesterday's presentations and sent the shares soaring.

Metadate, a drug for hyperactive children, has had disappointing sales in the cut-throat US market, but even here there has been good trial data in recent days, so the tide may be turning here, too.

Celltech has great technology and after an 18-month hiatus, is soon to start trialling four new drugs on humans. With a replacement for Peter Fellner, the chief executive, due by the end of the year, investors able to take a (very) long view might start to build a stake.

Christmas will make or break Body Shop

There are only 68 shopping days till Christmas. That may not be making you nervous yet, but it is making shareholders of Body Shop International sweat. This festive spending spree is make or break for the recovery at the ethical lotions and potions retailer.

Body Shop has been an erratic performer in recent years, a fact which forced the founder, Anita Roddick, into a non-executive role earlier this year. The new chief executive, Peter Saunders, at least hit market forecasts with half-year figures yesterday showing a £700,000 loss, compared with a £2.6m profit the previous year.

Worryingly, there was a big build up in unsold stocks, partly in advance of Christmas, partly because the company was preparing for the launch of its new range of make-up, and partly because it hasn't yet made enough progress in improving the efficiency of its supply chain. There was a worrying outflow of cash in the period, even if you ignore the £3.6m cost of axing 116 head office jobs. The interim dividend is paid out of reserves, so the final divi will depend on the cash position come March.

All of which means Christmas has got to be good. Mr Saunders is bullish, and it looks as if the new make-up range has driven a very strong pick up in UK sales in recent weeks. This is great news, because the UK has seemed a chronic underperformer, but it means there is still a harsh competitive and economic environment in the US.

Some of the City's influential retail sector pundits came away impressed, but it would be a big gamble to follow them in buying the shares. These were steady at 103.5p yesterday. That is a modest multiple of 10 times forecast earnings for the full year, but remember the forecasts are highly provisional. Potential investors should look for the New Year trading update before making the leap.

Fibernet remains a perilous investment

The telecoms company Fibernet is still desperately trying to demonstrate that it will be among the survivors of the particularly nasty storm raging through the telecoms sector.

Shareholders have been wiped out as sectormates such as Energis have been crushed under their debts and Fibernet is by no means in the clear yet.

The company has scaled back over-ambitious European operations to a single business in Frankfurt and is concentrating on selling telecoms services to businesses in the UK. It is an overcrowded market, and turnover even in the continuing divisions was down to £36.7m in the year to 31 August from £52.3m. The group plunged to a £91m pre-tax loss.

Fibernet says the second half of the year was better than the first with the value of new contracts rising to £26.9m from £9.8m. While that growth is clearly a positive sign, the fear among analysts is that it is taking longer for those new orders to convert into revenues.

The risks facing the business have been "significantly reduced" and the cash pile – which has dwindled to £34.3m from £95.7m a year ago – will be enough to see it through to profitability, the company insisted yesterday. Maybe. Not everyone agrees, and many fear a cash crunch is just over the horizon. Analysts at Investec predict Fibernet, which is not expected to be profitable until 2005, will be down to barely £12m of cash by August 2003. The shares, down 0.25p to 22.5p, remain a perilous investment. Sell.

Start your day with The Independent, sign up for daily news emails
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Recruitment Genius: Sales Adviser - OTE £24,500

£22500 - £24500 per annum: Recruitment Genius: Inbound and outbound calls with...

Recruitment Genius: Business Development Executive / Sales - OTE £40,000

£18000 - £40000 per annum: Recruitment Genius: This fast growing Insurance Bro...

Guru Careers: Research Associate / Asset Management Research Analyst

£40 - 45k (DOE) + Benefits: Guru Careers: A Research Associate / Research Anal...

Ashdown Group: Chief Technology Officer (CTO) - Glasgow

£90000 - £98000 per annum + benefits : Ashdown Group: A truly exciting opportu...

Day In a Page

Solved after 200 years: the mysterious deaths of 3,000 soldiers from Napoleon's army

Solved after 200 years

The mysterious deaths of 3,000 soldiers from Napoleon's army
Every regional power has betrayed the Kurds so Turkish bombing is no surprise

Robert Fisk on the Turkey conflict

Every regional power has betrayed the Kurds so Turkish bombing is no surprise
Investigation into wreck of unidentified submarine found off the coast of Sweden

Sunken sub

Investigation underway into wreck of an unidentified submarine found off the coast of Sweden
Instagram and Facebook have 'totally changed' the way people buy clothes

Age of the selfie

Instagram and Facebook have 'totally changed' the way people buy clothes
Not so square: How BBC's Bloomsbury saga is sexing up the period drama

Not so square

How Virginia Woolf saga is sexing up the BBC period drama
Rio Olympics 2016: The seven teenagers still carrying a torch for our Games hopes

Still carrying the torch

The seven teenagers given our Olympic hopes
The West likes to think that 'civilisation' will defeat Isis, but history suggests otherwise

The West likes to think that 'civilisation' will defeat Isis...

...but history suggests otherwise
The bald truth: How one author's thinning hair made him a Wayne Rooney sympathiser

The bald truth

How thinning hair made me a Wayne Rooney sympathiser
Froome wins second Tour de France after triumphant ride into Paris with Team Sky

Tour de France 2015

Froome rides into Paris to win historic second Tour
Fifteen years ago, Concorde crashed, and a dream died. Today, the desire to travel faster than the speed of sound is growing once again

A new beginning for supersonic flight?

Concorde's successors are in the works 15 years on from the Paris crash
I would never quit Labour, says Liz Kendall

I would never quit party, says Liz Kendall

Latest on the Labour leadership contest
Froome seals second Tour de France victory

Never mind Pinot, it’s bubbly for Froome

Second Tour de France victory all but sealed
Oh really? How the 'lowest form of wit' makes people brighter and more creative

The uses of sarcasm

'Lowest form of wit' actually makes people brighter and more creative
A magazine editor with no vanity, and lots of flair

No vanity, but lots of flair

A tribute to the magazine editor Ingrid Sischy
Foraging: How the British rediscovered their taste for chasing after wild food

In praise of foraging

How the British rediscovered their taste for wild food